Palliyil, SoumyaMawer, MarkAlwafi, SamiFogg, LilyBuda de Cesare, GiuseppeTan, TyngWalker, LouiseMacCalllum, DonnaPorter, AndrewMunro, Carol2023-08-082023-08-082022-04-19Palliyil, S, Mawer, M, Alwafi, S, Fogg, L, Buda de Cesare, G, Tan, T, Walker, L, MacCalllum, D, Porter, A & Munro, C 2022, 'Monoclonal antibodies targeting surface exposed epitopes of Candida albicans cell wall proteins confer in vivo protection in an infection model', Antimicrobial Agents and Chemotherapy, vol. 66, no. 4, e01957-21. https://doi.org/10.1128/aac.01957-210066-4804ORCID: /0000-0002-2236-8776/work/140425226ORCID: /0000-0003-0761-1755/work/162728995https://hdl.handle.net/2164/21437ACKNOWLEDGMENTS We gratefully acknowledge Kevin McKenzie and Lucy Wight from the University of Aberdeen Microscopy and Histology Facility for training and access to fluorescence microscopy and for their support and assistance in this work. We also gratefully acknowledge David Stead from Aberdeen Proteomics for his support and assistance with the Candida proteome analysis and the staff of the University of Aberdeen Medical Research Facility for their support and assistance with the mouse studies. This work was supported by the following research grants: the High Throughput and Fragment Screening Fund, Scottish Universities Life Sciences Alliance (SULSA); a seed corn award from the University of Aberdeen Wellcome Trust Institutional Strategic Support Fund; an M.Res. studentship by the Medical Research Council Centre for Medical Mycology at the University of Aberdeen (grant number MR/P501955/1); a Ph.D. studentship from the Institute of Medical Sciences, University of Aberdeen; a Ph.D. studentship from Taibah University and a Saudi Government scholarship; and a Ph.D. studentship by the European Union’s Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant agreement number H2020-MSCA-ITN-2014-642095 (OPATHY). C.A.M., S.P., and A.J.P. contributed to the concept and study design. C.A.M. and S.P. developed the methodology. S.A.A. and L.F. performed recombinant antibody generation and ELISAs. L.F. and M.M. completed IgG reformatting and the production of mAbs for animal studies. M.M., T.H.T., and L.A.W. performed ELISAs and immunofluorescence staining. M.M. performed macrophage assays, and D.M.M. planned, conducted, and analyzed animal studies. C.A.M., S.P., and A.J.P. contributed to funding acquisition and project administration, and C.A.M., S.P., and L.A.W. contributed to the supervision and training of M.Res. and Ph.D. students. S.P. wrote the original draft, and C.A.M., D.M.M., and A.J.P. completed review and editing. All authors had full access to the data and approved the manuscript before it was submitted by the corresponding author(s). S.P., A.J.P., and C.A.M. are inventors on a patent related to the development of antifungal antibodies to surface-exposed epitopes of fungal pathogens owned by the University of Aberdeen. All other authors declare that they have no competing interests.2942094engCandida albicansanti-Candida mAbsimmunotherapymonoclonal antibodiesR MedicineSupplementary InformationRJournal article10.1128/aac.01957-21664